Abraxis BioScience, Inc. has entered into an agreement with AstraZeneca UK Ltd., under which Abraxis would re-acquire the exclusive rights to market Abraxane (paclitaxel protein-bound particles for injectable suspension) in the U.S. The agreement is subject to approval by the board of directors of Abraxis.     “We believe the time has come to further build our commercialization platform for Abraxane in the U.S.,” said Patrick Soon-Shiong, M.D., chairman and chief executive officer of Abraxis ...